Preprint
Review
Version 1
Preserved in Portico This version is not peer-reviewed
DG9, a Versatile Cell-Penetrating Peptide to Enhance Delivery of Antisense Oligonucleotide-Based Therapeutics
Version 1
: Received: 26 August 2023 / Approved: 28 August 2023 / Online: 29 August 2023 (09:48:58 CEST)
A peer-reviewed article of this Preprint also exists.
Haque, U.S.; Yokota, T. Enhancing Antisense Oligonucleotide-Based Therapeutic Delivery with DG9, a Versatile Cell-Penetrating Peptide. Cells 2023 , 12 , 2395.
Haque, U.S.; Yokota, T. Enhancing Antisense Oligonucleotide-Based Therapeutic Delivery with DG9, a Versatile Cell-Penetrating Peptide. Cells 2023, 12, 2395.
Copy
Haque, U.S.; Yokota, T. Enhancing Antisense Oligonucleotide-Based Therapeutic Delivery with DG9, a Versatile Cell-Penetrating Peptide. Cells 2023 , 12 , 2395.
Haque, U.S.; Yokota, T. Enhancing Antisense Oligonucleotide-Based Therapeutic Delivery with DG9, a Versatile Cell-Penetrating Peptide. Cells 2023, 12, 2395.
Copy
CANCEL
COPY CITATION DETAILS
Abstract
Keywords: Antisense Oligonucleotides, Cell Penetrating Peptides, Delivery, DG9 peptide, Phosphorodiamidate morpholino oligomers (PMO), Pip, R6G.
Keywords
Antisense Oligonucleotides; Cell Penetrating Peptides; Delivery; DG9 peptide; Phosphorodi-amidate morpholino oligomers (PMO); Pip; R6G
Subject
Medicine and Pharmacology, Neuroscience and Neurology
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Comments (0)
We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.
* All users must log in before leaving a comment
what’s this?
Add a record of this review to Publons to track and showcase your reviewing expertise across the world’s journals.
×
